Exosomes from both normal BMSCs and BMSCs from AML patients reduce the cytotoxic effects of the nucleoside analogue cytarabine on MOLM-14 cells with FLT3-ITD (internal tandem duplication) mutation, and only AML-BMSC derived exosomes provided such protection from AC220 (a FLT3 kinase inhibitor) treatment [50]. This evidence concerns the gene FLT3 and acute myeloid leukemia.